TNFRSF8 and classic Hodgkin lymphoma: Consequently, clinical efficacy of anti-PD1 checkpoint inhibition by the anti-PD-1 antibody nivolumab and targeting of malignant cHL cells with the anti-CD30 antibody-drug conjugate Brentuximab vedotin (BV) alone and in combination has been demonstrated in adult (16–19) and partly in pediatric R/R cHL patients (20, 21).